坦桑尼亚西北部疑似病毒学失败患者中HIV耐药性的患病率与模式
该研究在坦桑尼亚西北部纳入317例接受抗逆转录病毒治疗(ART)的患者,以单次血浆HIV RNA>1000拷贝/mL作为疑似病毒学失败标准,对其中56例成功进行基因型检测;48例(85.7%)携带至少一个主要耐药相关突变,基于利托那韦增效蛋白酶抑制剂的方案未检出耐药相关突变。作者认为单次高病毒载量可预测病毒学失败,可能避免从一线向高遗传屏障二线方案转换的延迟。
要点
- 317例接受ART患者中64例(20.2%)符合疑似病毒学失败标准。
- 56例成功基因型检测中48例(85.7%)携带至少一个主要耐药相关突变。
- 基于利托那韦增效蛋白酶抑制剂的ART方案未检出耐药相关突变。
核心结论
- 单次血浆病毒载量高于WHO阈值(1000拷贝/mL)与高比例耐药相关突变相关,作者认为单次高病毒载量测量可用于预测病毒学失败并避免从一线向高遗传屏障二线方案转换的延迟。
研究设计与样本
- 研究在坦桑尼亚西北部进行,对接受ART的患者以单次血浆HIV RNA>1000拷贝/mL定义为疑似病毒学失败,提取血浆HIV-1 RNA并分析HIV pol基因的蛋白酶区和部分逆转录酶区。
- 病毒载量检测共317例患者,其中64例(20.2%)符合疑似病毒学失败标准,成功对56份样本进行基因型检测。
主要发现
- 317例接受病毒载量检测的患者中,64例(20.2%)为疑似病毒学失败。
- 成功基因型检测的56例中,48例(85.7%)携带至少一个主要耐药相关突变。
- 逆转录酶区常见突变为M184V(75%)、T215Y(41.1%)、K103N(39.3%)、M41L(32.1%)、D67DN(30.3%)、G190A(28.6%)和A98G(26.8%)。
- 基于利托那韦增效蛋白酶抑制剂的ART方案中未检出耐药相关突变。
关键数值与推荐
- 坦桑尼亚国家指南将病毒学失败定义为间隔3个月连续两次病毒载量检测结果均高于WHO阈值(1000拷贝/mL)。
- 本研究以单次血浆HIV RNA>1000拷贝/mL作为疑似病毒学失败标准。
临床怎么用
- 作者认为单次高病毒载量测量可用于预测病毒学失败,并避免从一线向高遗传屏障二线方案转换的延迟。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: More than 15 million people in sub-Saharan Africa receive ART. Treatment failure is common, but the role of HIV drug resistance in treatment failure is largely unknown because drug resistance testing is not routinely done. This study determined the prevalence and patterns of HIV drug resistance in patients with suspected virological failure. MATERIALS AND METHODS: A single high viral load of >1000 viral RNA copies/mL of plasma at any point during ART was considered as suspected virological failure. HIV-1 RNA was extracted from plasma samples of these patients using the QIAamp Viral RNA kit. The protease and part of the RT regions of the HIV pol gene were characterized. RESULTS: Viral load was determined in 317 patients; 64 (20.2%) had suspected virological failure. We successfully genotyped 56 samples; 48 (85.7%) had at least one major resistance-associated mutation (RAM). Common mutations in RT were M184V (75%), T215Y (41.1%), K103N (39.3%), M41L (32.1%), D67DN (30.3%), G190A (28.6%) and A98G (26.8%). No RAMs were detected in ART regimens based on a ritonavir-boosted PI. CONCLUSIONS: The Tanzanian national guidelines define 'virological failure' as two consecutive viral load measurement results, at 3 month intervals, above the WHO threshold (1000 copies/mL). Here, we show that a single viral load above the WHO threshold is associated with high rates of RAMs. This suggests that a single high viral load measurement could be used to predict virological failure and avoid delays in switching patients from first-line to higher genetic barrier second-line regimens.
引用
- Henerico S, Mikasi SG, Kalluvya SE, et al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania. J Antimicrob Chemother. 2022. PMID: 35107140. doi:10.1093/jac/dkab406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。